Teva Pharma, Perrigo Announce U.S. Launch Of Generic Temozolomide - Quick Facts

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) and Perrigo Co. (PRGO) announced the launch of the generic equivalent to Temodar. Teva would manufacture, market and distribute the product in the U.S. and both the companies would equally share in the cost and profitability of the product in the U.S. Teva was first to file, making the product eligible for 180 days of marketing exclusivity.

This product is the generic equivalent to Temodar, which is treated for adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment and refractory anaplastic astrocytoma patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine. Temodar had annual sales of roughly $423 million in the U.S., according to IMS data as of December 31, 2012.

According to the companies, this product launch provides a quality alternative, making cancer therapy more cost effective for patients who suffer from this devastating cancer.